查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840850

依动物类型、产品类型、通路、治疗领域及给药途径动物用药品市场－2025-2032年全球预测

Veterinary Medicine Market by Animal Type, Product Type, Distribution Channel, Therapeutic Area, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，动物用药品市场规模将达到 839.1 亿美元，复合年增长率为 7.94%。

关键市场统计数据
基准年 2024 455.1亿美元
预计年份：2025年 491亿美元
预测年份 2032 839.1亿美元
复合年增长率 (%) 7.94%

为决策者提供一份简洁的兽医生态系统发展概况，重点在于综合护理、预防策略和商业性要务。

动物用药品产业正处于曲折点，技术创新、消费模式的改变以及监管环境的演变正在重塑临床实践、产品开发和分销。本执行摘要简要概述了高阶领导者在应对短期挑战和掌握长期策略机会时必须考虑的结构性驱动因素、竞争动态和营运影响。

近年来，兽医学已从单一治疗转向以预防为主、以诊断主导的决策和以数据主导的综合动物健康管理。这一趋势在伴侣动物照护领域尤其明显，宠物饲主越来越重视便利性、数位互动和更高的照护标准。同时，在畜牧业和马匹领域，对生物安全、生产力和饲料转换率的日益关注也推动了产品组合和服务内容的转变。

因此，企业领导者需要调整其研发重点、市场推广模式和供应链韧性，以适应这些多领域的变革。本导言为后续章节奠定了框架，这些章节包括整个生态系统的转型变化、2025年关税相关贸易影响的预测、细分市场层面的考虑、区域动态、竞争定位、可操作的建议以及支撑我们研究结果的调查方法。本书有意整合了物种、产品、分销、治疗和给药等方面的知识，旨在帮助相关人员将策略意义说明为切实可行的措施。

诊断主导护理、数位化管道和供应链本地化如何重塑兽医学领域的产品开发和服务交付

一场根本性的变革正在改变动物保健服务的提供方式、产品的研发方式以及商业性价值的取得方式。更快速的照护现场诊断和先进的影像技术能够实现早期疗育，从而推动对标靶药物和疫苗的需求。这些以诊断为驱动的模式正在重塑犬猫等伴侣动物的临床通讯协定，同时也影响牛、家禽和猪等畜群的健康管理策略。

另一项变革性趋势是数位医疗和远距医疗模式的快速普及。远端医疗和数位分诊平台正成为传统诊所的有效补充，尤其是在都市区宠物市场和诊所密度较低的地区。这些数位化能力正在改变分销格局，为网路商店与药房和兽医诊所合作提供一体化医疗服务创造了机会。它们还有助于更有效地管理各个治疗领域的慢性疾病，例如抗感染药感染疾病和抗发炎药物。

供应链在地化和製造创新构成了第三大转变。为因应地缘政治的不确定性和疫情带来的教训，企业正在加速投资本地化的配方和填充能力，以及针对当地情况量身定制的替代给药途径，例如注射剂、口服剂和外用剂。最后，对配方科学和新型疫苗平台的日益重视，例如针对特异性物种需求的重组疫苗（用于马匹）和提高牲畜灭活疫苗的稳定性，正在改变产品开发蓝图和监管沟通策略。

评估2025年美国关税对动物用药品供应链、采购选择和定价动态的策略影响

贸易政策变化和关税会对动物用药品价值链的投入成本、供应链策略和定价权产生重大影响。美国已实施或提案于2025年实施的关税迫使製造商和经销商重新评估其活性药物​​原料药、疫苗组成和诊断设备的筹资策略。这些关税可能会增加进口原材料和成品的到岸成本，促使企业评估供应商多元化、近岸外包和长期采购协议等方案。

随着企业做出应对，物流和库存策略也将随之调整。企业将增加安全库存或转向多通路采购以降低风险敞口，而合约製造外包和经销商将重新评估合约条款并提高风险分配的透明度。同时，定价纪律至关重要。企业必须考虑如何在成本回收和竞争定位之间取得平衡，尤其是在价格敏感的管道，例如网路商店和药局。在存在替代品的治疗领域，例如学名药药和品牌处方药，关税造成的成本差异可能会加速替代品的出现，或者相反，增强对国产品牌的需求。

监管和政策应对措施将进一步影响结果。政策制定者可以针对基本动物用药品实施有针对性的豁免，以保护动物健康和食品安全，并透过税额扣抵和津贴奖励国内生产。因此，高阶领导人应密切关注贸易政策的发展，同时与行业协会和监管机构合作，倡导建立可预测的贸易框架，以保护动物健康和该行业的韧性。

细分市场层面的策略指导，协调物种特定需求、产品模式、治疗重点、分销管道和给药途径，以做出更明智的决策。

细緻入微的市场区隔观点对于将市场动态转化为可执行的商业计划至关重要。相关人员应根据动物类型，制定不同的策略，例如：伴侣动物市场（犬猫主导临床需求和消费者支出）、马匹市场（马匹具有独特的表现和健康需求）以及畜牧业市场（包括牛、鸡和猪，规模、生物安全和饲料转换率是产品推广的关键因素）。每种动物类别都有不同的购买模式、监管节点和渠道偏好。

按产品类型划分，可以发现不同的创新和商业化路径。诊断产品包括影像学技术和感染疾病检测，这些技术越来越多地应用于临床第一线，从而影响下游药物和疫苗的取得。药用饲料添加剂旨在提高畜牧生产效率，需要与饲料生产商和农场管理系统密切合作。药品包括学名药、非处方药和处方笺药，每种药品都面临不同的监管负担和利润率。疫苗包括灭活疫苗、减毒活病毒疫苗疫苗和重组疫苗，需要专门的低温运输和给药能力。

分销管道细分——包括网路商店、药局和兽医诊所——决定了客户获取模式和利润结构。线上通路提供便利的购买方式和订阅模式，药局提供非处方药零售，而诊所则结合了诊断和照护现场治疗。不同的治疗领域——抗感染药感染疾病、抗发炎药物、循环系统药物和抗寄生虫药物——决定了研发重点。抗感染药感染疾病需要针对抗生素、抗真菌药物和抗病毒药物分别制定有针对性的管理策略。杀寄生虫药物分为体外杀寄生虫药物和体内杀寄生虫药物，二者的给药方案各有不同。给药途径——吸入、注射、口服或外用——也会进一步影响产品设计、使用者训练需求和市场接受度曲线。

区域动态和跨境因素影响着世界主要地区的监管协调、生产决策和分销策略

区域动态对动物保健领域的管理体制、分销架构和投资重点有显着影响。动物用药品。这些特点提高了都市区每隻动物的就医支出，并为诊断和处方笺药的销售创造了有利的管道。相较之下，欧洲、中东和非洲地区（EMEA）呈现异质性，许多欧洲市场拥有先进的法律规范和高标准的兽医体系，而中东和北非地区（MENA）的某些司法管辖区则将动物健康和生物安全置于优先地位，以保护食品供应链。

亚太地区兽医服务正经历快速现代化，製造业投资不断增长，对伴侣动物和生产动物产品的需求也日益增加。在所有地区，供应链韧性和监管协调仍然是重中之重，尤其对于疫苗和生技药品，因为它们需要冷链完整性和严格的品管。区域贸易协定和生产激励措施影响企业生产和分销基地的选址，以及它们如何制定打入市场策略，以平衡上市速度、合规性和成本效益。

因此，区域领导者和全球团队必须紧密合作。成功的策略是将本地市场情报、监管专业知识以及与区域经销商的伙伴关係相结合，同时利用研发和製造方面的集中化主导来维持产品品质和规模经济效益。

结合产品创新、伙伴关係和商业性灵活性的竞争策略，可确保动物用药品在临床上的应用和永续成长。

动物用药品领域的竞争地位取决于产品系列、垂直整合和策略伙伴关係关係。领先企业往往将疫苗平台、专有药物和诊断能力的优势与覆盖诊所、药房和线上管道的广泛分销和服务相结合。投资于製剂科学和给药技术的企业在使用者便利性和依从性方面更具优势，尤其是在慢性病治疗和寄生虫控制方案方面。

与饲料生产商、诊断创新者和受託製造厂商建立合作关係，可以加快含药饲料添加剂和特殊生技药品的上市速度。授权和共同开发契约是高效将重组疫苗和先进诊断产品推向市场的常用手段，而策略性收购则可以弥补影像和即时检测技术的能力缺口。此外，积极实施抗菌药物管理和透明供应链实践的公司，更容易赢得监管机构、兽医和终端客户的信任。

最后，灵活的商业模式，例如针对慢性病管理的订阅服务、面向诊所的综合诊断和治疗服务，以及针对非处方药的直接面向消费者的电子商务策略，将使市场领导者与快速追随者区分开来。对真实世界证据生成和兽医教育计画的投资将进一步加强临床应用和长期品牌忠诚度。

一系列务实的策略倡议，重点在于诊断、灵活采购、通路差异化、物种特异性研发以及监管沟通，旨在推动商业成功。

为了克服复杂性并抓住机会，产业领导者应优先考虑几项高影响力措施。首先，投资诊断整合和即时数据系统将有助于做出更精准的治疗决策，减少不合理使用抗生素，并支持向支付者和终端用户传递价值资讯。这需要对即时检测、影像技术和分析技术进行协调投资，以便将临床讯号转化为可执行的通讯协定。

其次，企业应重新评估其采购和生产布局，以降低关税和地缘政治风险。在可行的情况下，关键投入品的近岸外包或双重采购策略，以及建立长期供应商伙伴关係关係，可以在不牺牲成本竞争力的前提下增强抵御风险的能力。第三，企业应采取差异化的分销策略，充分利用其线上通路、药房网络和诊所关係的优势。这意味着要建构针对特定管道的价值主张和服务模式，以反映独特的客户体验历程。

第四，开发平臺与特定物种的需求和使用偏好相匹配，可以提高产品普及率。优先研发便于饲主农场工作人员使用的配方，并推动稳定性更高的疫苗平台，可降低使用门槛。最后，积极参与监管事务和倡议，可以保护产品完整性，并促进产品更顺利地进入市场。这些措施共同构成了将洞见转化为行动的实际可行的蓝图。

我们以实证为基础的研究途径结合了依证访谈、二手检验和情境压力测试，从而得出可操作、可直接用于决策的洞见。

本执行摘要的调查方法结合了多种手段，以确保其可靠性和有效性。主要研究包括：对伴侣动物、马匹和牲畜兽医进行结构化访谈；与製药、疫苗和诊断领域的资深商业领袖进行讨论；以及与线上管道、零售药局和诊所管道的分销合作伙伴进行咨询。这些访谈提供了关于产品推广驱动因素、给药偏好和通路经济效益的第一线观点。

二次分析利用同行评审文献、监管指南、行业技术标准和上市公司披露信息，检验了产品创新、生产能力和政策发展趋势。贸易政策和供应链评估纳入了公开的关税公告和政府声明，以模拟预期的营运应对措施，但并未得出量化的市场估计值。为减少偏差并提高适用性，对不同产品类型、治疗领域和地区进行了交叉检验。

最后，调查方法强调了实际应用性：透过与商业和监管专家进行情境研讨会，对研究结果进行压力测试，以完善策略建议，并确保提案的行动在现有的组织约束和时间范围内是可行的。

总结性分析将物种特定优先事项、不断演变的分销模式和政策主导的供应链应对措施联繫起来，并为领导者提供了明确的策略启示。

摘要：兽医领域正朝着以数位化管道和在地化生产策略为支撑的、以诊断主导的综合医疗模式发展。从犬猫等伴侣动物到马、牛、鸡、猪等生产动物，不同物种在产品开发、监管沟通和分销渠道设计等方面都需要量身定制的解决方案。产品创新的重点也日益转向诊断赋能、先进的疫苗平台以及能够适应实际用药限制的易用型製剂。

主要市场贸易政策（包括关税）的转变迫使企业调整采购和库存策略，同时与政策制定者合作，以保护重要的动物用药品。不同区域的市场动态凸显了市场准入和生产决策的必要性，这些决策必须反映美洲、欧洲、中东和非洲以及亚太地区的法规环境和物流实际情况。对于商业领袖而言，与竞争对手合作、投资于照护现场能力以及积极参与监管事务，是实现永续成长和降低风险的有效途径。

综上所述，这些结论为高阶主管提供了一个策略视角，以便他们优先考虑投资、协调跨职能团队，并加快推进各项工作，从而在动物健康结果和组织韧性方面取得可衡量的改进。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合远端医疗平台，进行远距兽医咨询，以改善病患治疗效果，减少诊所拥挤。
  • 宠物癌症发生率的不断上升，推动了兽医肿瘤治疗领域对生技药品和生物相似药的需求。
  • 推出用于持续收集动物健康数据和进行预测分析的智慧穿戴监测设备
  • 将行动兽医服务扩展到服务不足的农村地区，可以改善人们获得预防性护理的机会。
  • 人工智慧演算法在宠物影像和疾病检测的应用日益广泛
  • 基于动物遗传学和微生物组分析的个人化营养和膳食补充剂配方发展
  • 促进对具有新型作用机制的新型杀寄生虫药物的监管，以对抗抗蠕虫药物抗药性。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依动物类型分類的动物用药品市场

  • 伴侣动物
    • 猫
    • 狗
  • 马科部门
    • 马
  • 家畜
    • 牛
    • 家禽
    • 猪

第九章 依产品类型分類的动物用药品市场

  • 诊断
    • 影像
    • 感染疾病
  • 药品和饲料添加剂
  • 製药
    • 学名药
    • 非处方药
    • 处方药
  • 疫苗
    • 灭活疫苗
    • 活病毒疫苗
    • 重组

第十章 按分销管道分類的动物用药品市场

  • 网路商店
  • 药局
  • 兽医诊所

第十一章 依治疗领域分類的动物用药品市场

  • 抗感染药物
    • 抗生素
    • 抗真菌药物
    • 抗病毒药物
  • 抗发炎药
  • 心血管系统
  • 杀寄生虫剂
    • 体外寄生虫杀灭剂
    • Endectocides

第十二章 依给药途径分類的动物用药品市场

  • 吸入
  • 注射
  • 口服
  • 外用

第十三章 按地区分類的动物用药品市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章动物用药品市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国动物用药品市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Elanco Animal Health Incorporated
    • IDEXX Laboratories, Inc.
    • Ceva Sante Animale SA
    • Vetoquinol SA
    • Virbac SA
    • Dechra Pharmaceuticals plc
    • Phibro Animal Health Corporation
Product Code: MRR-221461476D1E

The Veterinary Medicine Market is projected to grow by USD 83.91 billion at a CAGR of 7.94% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 45.51 billion
Estimated Year [2025] USD 49.10 billion
Forecast Year [2032] USD 83.91 billion
CAGR (%) 7.94%

A concise orientation to the evolving veterinary medicine ecosystem emphasizing integrated care, preventive strategies, and commercial imperatives for decision-makers

The veterinary medicine sector stands at an inflection point where technological innovation, shifting consumption patterns, and evolving regulatory landscapes are reshaping clinical practice, product development, and distribution. This executive summary provides a concise synthesis of the structural drivers, competitive dynamics, and operational implications that senior leaders must consider to navigate near-term disruptions and longer-term strategic opportunities.

Over recent years, veterinary care has moved beyond episodic treatment toward integrated animal health management that emphasizes preventive care, diagnostics-led decision making, and data-driven outcomes. These trends are especially pronounced in companion animal care, where pet owners increasingly prioritize convenience, digital engagement, and higher standards of therapeutic outcomes. At the same time, livestock and equine segments are experiencing heightened scrutiny on biosecurity, productivity, and feed efficiency, prompting shifts in product mix and service delivery.

Consequently, corporate leaders must align R&D priorities, go-to-market models, and supply chain resilience with these multi-vector changes. This introduction frames the subsequent sections, which explore transformative shifts across the ecosystem, tariff-related trade implications projected for 2025, segmentation-level insights, regional dynamics, competitive positioning, actionable recommendations, and the research approach underpinning the findings. The narrative purposefully integrates species, product, distribution, therapeutic, and administration dimensions so that stakeholders can translate strategic implications into practical initiatives.

How diagnostics-led care, digital channels, and supply chain localization are redefining product development and service delivery across veterinary medicine

Fundamental shifts are transforming how veterinary health services are delivered, how products are developed, and how commercial value is captured. One major change is the convergence of diagnostics and therapeutics: faster, point-of-care diagnostics and advanced imaging are enabling earlier intervention, which in turn drives demand for targeted pharmaceuticals and vaccines. This diagnostic-enabled model is reshaping clinical protocols for companion animals such as cats and dogs, while also informing herd health strategies for cattle, poultry, and swine.

Another transformative movement is the rapid adoption of digital and remote care models. Telemedicine and digital triage platforms have become a viable complement to traditional clinic visits, particularly in urban companion animal markets and in regions where clinic density is low. These digital capabilities are altering the distribution landscape, creating opportunities for online stores to partner with pharmacies and veterinary clinics to provide integrated care journeys. They also permit more efficient chronic disease management across therapeutic areas such as anti-infectives and anti-inflammatories.

Supply chain localization and manufacturing innovation constitute a third major shift. In response to geopolitical uncertainty and pandemic lessons, firms are accelerating investments in localized formulation and fill-finish capacity, as well as in alternative routes of administration such as injectables, oral formulations, and topical therapies that align with field conditions. Finally, there is a rising emphasis on formulation science and novel vaccine platforms that address species-specific needs-ranging from recombinant vaccines for equine applications to improved inactivated vaccine stability for livestock-thereby changing product development roadmaps and regulatory engagement strategies.

Assessing the strategic consequences of United States tariff measures in 2025 for supply chains, sourcing choices, and pricing dynamics across veterinary product categories

Trade policy changes and tariff actions can materially influence input costs, supply chain strategies, and pricing dynamics across the veterinary medicines value chain. In the context of tariffs enacted or proposed in the United States in 2025, manufacturers and distributors are facing renewed pressure to reassess sourcing strategies for active pharmaceutical ingredients, vaccine components, and diagnostic equipment. These tariff measures tend to increase landed costs for imported raw materials and finished goods, which encourages firms to evaluate options including supplier diversification, nearshoring, and long-term purchasing agreements.

As companies respond, logistics and inventory strategies will also adapt. Firms may increase safety stock levels or shift to multi-sourcing to mitigate exposure, while contract manufacturers and distributors reassess contractual terms to allocate risk more explicitly. In parallel, pricing discipline becomes critical: firms must consider how to balance cost recovery with competitive positioning, especially in price-sensitive channels such as online stores and pharmacies. For therapeutic categories where alternatives exist-such as generic pharmaceuticals versus brand prescription drugs-tariff-induced cost differentials can accelerate substitution or, conversely, reinforce demand for domestically produced branded solutions.

Regulatory and policy responses will further shape outcomes. Policymakers may implement targeted exemptions for essential veterinary products to preserve animal health and food security, or they may incentivize domestic production through tax credits and grants. Therefore, senior leaders should monitor trade policy developments closely while engaging with industry associations and regulatory bodies to advocate for predictable trade frameworks that protect both animal health and sectoral resilience.

Segment-level strategic guidance that aligns species-specific needs, product modalities, therapeutic priorities, distribution channels, and routes of administration for better decision-making

A nuanced segmentation view is indispensable for translating market dynamics into actionable commercial plans. Based on animal type, stakeholders must differentiate strategies across companion animal segments-where cats and dogs dominate clinical demand and consumer spending-from equine markets, which have unique performance and wellness needs centered on horses, and livestock sectors comprising cattle, poultry, and swine where scale, biosecurity, and feed efficiency drive product adoption. Each animal category presents distinct purchasing patterns, regulatory touchpoints, and channel preferences.

Product type segmentation reveals divergent innovation and commercialization pathways. Diagnostics encompass imaging modalities and infectious disease assays that are increasingly deployed at point of care, influencing downstream pharmaceutical and vaccine utilization. Medicated feed additives target production efficiency in livestock, requiring close alignment with feed manufacturers and farm management systems. Pharmaceuticals span generic drugs, over-the-counter remedies, and prescription medicines, each with different regulatory burdens and margin profiles. Vaccines include inactivated, live attenuated, and recombinant platforms, and they demand specialized cold-chain and administration capabilities.

Distribution channel segmentation-consisting of online stores, pharmacies, and veterinary clinics-determines customer access models and margin structures. Online channels excel in convenience and subscription models, pharmacies provide retail reach for OTC products, and clinics combine diagnosis with point-of-care treatment. Therapeutic area distinctions across anti-infectives, anti-inflammatories, cardiovascular agents, and parasiticides inform R&D prioritization; within anti-infectives, antibiotics, antifungals, and antivirals each require targeted stewardship strategies, while parasiticides separate into ectoparasiticides and endectocides with differing administration regimens. Route of administration considerations-covering inhalation, injectable, oral, and topical formats-further influence product design, user training needs, and adoption curves.

Regional dynamics and cross-border considerations that influence regulatory alignment, manufacturing decisions, and distribution strategies across major global regions

Regional dynamics materially shape regulatory regimes, distribution architectures, and investment priorities across veterinary medicine. In the Americas, markets often feature mature companion animal care ecosystems, a strong retail pharmacy presence, and expanding digital health adoption; these characteristics support higher per-animal spend in urban centers and create attractive channels for diagnostics and prescription pharmaceuticals. In contrast, the Europe, Middle East & Africa region displays heterogeneity, with advanced regulatory frameworks and high veterinary standards in many European markets, while certain Middle East and African jurisdictions prioritize livestock health and biosecurity to safeguard food supply chains.

Asia-Pacific is marked by rapid modernization of veterinary services, with growing investment in manufacturing capacity and rising demand for both companion and production animal products. Across all regions, supply chain resilience and regulatory harmonization remain salient priorities, especially for vaccines and biologics that require cold-chain integrity and stringent quality controls. Regional trade agreements and local manufacturing incentives influence where companies choose to site production and distribution hubs, and they affect how firms design market entry strategies that balance speed to market with compliance and cost efficiency.

Consequently, regional leaders and global teams must coordinate closely; successful approaches integrate local market intelligence, regulatory affairs expertise, and partnerships with regional distributors, while also leveraging center-led capabilities in R&D and manufacturing to maintain quality and scale economies.

Competitive strategies that combine product innovation, partnerships, and commercial agility to secure clinical adoption and sustainable growth in veterinary medicine

Competitive positioning in veterinary medicine is shaped by product portfolios, vertical integration, and strategic partnerships. Leading firms tend to combine strengths in vaccine platforms, proprietary pharmaceuticals, and diagnostic capabilities with broad distribution networks and service offerings that span clinics, pharmacies, and online channels. Companies investing in formulation science and delivery technologies secure advantages in user convenience and adherence, particularly for chronic therapeutic areas and parasiticide regimens.

Collaboration remains a key tactic: alliances with feed producers, diagnostic innovators, and contract manufacturing organizations accelerate route-to-market for medicated feed additives and specialty biologics. Licensing and co-development agreements are common for bringing recombinant vaccines and advanced diagnostics to market efficiently, while strategic acquisitions can fill capability gaps in imaging or point-of-care assay technologies. Additionally, firms that proactively engage in antimicrobial stewardship and transparent supply chain practices earn greater trust among regulators, veterinarians, and end customers.

Finally, agility in commercial models-such as subscription services for chronic disease management, bundled diagnostics-therapy offerings for clinics, and direct-to-consumer e-commerce strategies for OTC products-differentiates market leaders from fast followers. Investment in real-world evidence generation and veterinarian education programs further strengthens clinical adoption and long-term brand loyalty.

A pragmatic set of strategic moves focused on diagnostics, resilient sourcing, channel differentiation, species-aligned R&D, and regulatory engagement to drive commercialization success

Industry leaders should prioritize a few high-impact initiatives to navigate complexity and capture opportunities. First, investing in diagnostic integration and real-time data systems will enable more precise therapeutic decisions, reduce inappropriate antimicrobial use, and support value communication to payers and end users. This requires coordinated investments in point-of-care testing, imaging capabilities, and analytics that translate clinical signals into actionable protocols.

Second, companies should reassess sourcing and manufacturing footprints to mitigate tariff and geopolitical risks. Where feasible, nearshoring or dual-sourcing strategies for critical inputs, along with long-term supplier partnerships, will enhance resilience without sacrificing cost competitiveness. Third, firms need to adopt differentiated distribution strategies that exploit the strengths of online channels, pharmacy networks, and clinic relationships; this means creating channel-specific value propositions and service models that reflect distinct customer journeys.

Fourth, aligning R&D pipelines with species-specific needs and administration preferences will improve adoption rates. Prioritizing formulations that simplify administration for owners and farm staff, and advancing vaccine platforms with improved stability, will lower barriers to use. Lastly, proactive regulatory engagement and participation in stewardship initiatives will protect product credibility and enable smoother market access. Together, these actions form a pragmatic roadmap for translating insight into execution.

An evidence-based research approach combining qualitative interviews, secondary validation, and scenario stress-testing to derive practical, decision-ready insights

The research underpinning this executive summary combines multiple methodological approaches to ensure reliability and relevance. Primary qualitative research included structured interviews with veterinarians across companion, equine, and livestock practices, discussions with senior commercial leaders in pharmaceuticals, vaccines, and diagnostics, and consultations with distribution partners operating online, retail pharmacy, and clinic channels. These interviews provided frontline perspectives on adoption drivers, administration preferences, and channel economics.

Secondary analysis drew on peer-reviewed literature, regulatory guidance, industry technical standards, and public company disclosures to validate trends in product innovation, manufacturing capacity, and policy developments. Trade policy and supply chain assessments incorporated publicly available tariff announcements and government statements to model likely operational responses without producing quantitative market estimates. Cross-validation exercises were used to triangulate insights across species, product types, therapeutic areas, and regions to reduce bias and enhance applicability.

Finally, the methodology emphasized practical applicability: findings were stress-tested through scenario workshops with commercial and regulatory experts to refine strategic recommendations and to ensure that suggested actions are feasible within typical organizational constraints and timelines.

Concluding synthesis that links species-specific priorities, evolving distribution models, and policy-driven supply chain responses into clear strategic implications for leaders

In summary, the veterinary medicine landscape is evolving toward integrated, diagnostic-led care supported by digital channels and localized manufacturing strategies. Species differences-from companion animals such as cats and dogs to horses and to production animals like cattle, poultry, and swine-require tailored approaches across product development, regulatory engagement, and distribution design. Product innovation is increasingly centered on diagnostic enablement, advanced vaccine platforms, and user-friendly formulations that match real-world administration constraints.

Trade policy shifts, including tariff actions in major markets, are prompting companies to reconfigure sourcing and inventory strategies while engaging with policymakers to safeguard essential animal health products. Regionally differentiated market dynamics underscore the need for market entry and manufacturing decisions that reflect local regulatory environments and logistical realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. For commercial leaders, the combination of competitive collaboration, investment in point-of-care capabilities, and disciplined regulatory engagement presents a coherent path to sustain growth and mitigate risk.

Taken together, these conclusions provide a strategic lens for executives to prioritize investments, align cross-functional teams, and accelerate initiatives that deliver measurable improvements in animal health outcomes and organizational resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of telemedicine platforms for remote veterinary consultations improving patient outcomes and reducing clinic congestion
  • 5.2. Rising demand for biologics and biosimilars in veterinary oncology treatments driven by growing pet cancer incidence
  • 5.3. Adoption of smart wearable monitoring devices for continuous animal health data collection and predictive analytics
  • 5.4. Expansion of mobile veterinary services to underserved rural areas enabling improved access to preventive care
  • 5.5. Increasing use of artificial intelligence algorithms for diagnostic imaging and disease detection in pets
  • 5.6. Growth of personalized nutrition and nutraceutical formulations based on genetics and microbiome profiling of animals
  • 5.7. Regulatory acceleration of novel parasiticides leveraging novel modes of action to combat anthelmintic resistance

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Medicine Market, by Animal Type

  • 8.1. Companion Animal
    • 8.1.1. Cat
    • 8.1.2. Dog
  • 8.2. Equine
    • 8.2.1. Horse
  • 8.3. Livestock
    • 8.3.1. Cattle
    • 8.3.2. Poultry
    • 8.3.3. Swine

9. Veterinary Medicine Market, by Product Type

  • 9.1. Diagnostics
    • 9.1.1. Imaging
    • 9.1.2. Infectious Disease
  • 9.2. Medicated Feed Additives
  • 9.3. Pharmaceuticals
    • 9.3.1. Generic Drugs
    • 9.3.2. Over The Counter Drugs
    • 9.3.3. Prescription Drugs
  • 9.4. Vaccines
    • 9.4.1. Inactivated
    • 9.4.2. Live Attenuated
    • 9.4.3. Recombinant

10. Veterinary Medicine Market, by Distribution Channel

  • 10.1. Online Stores
  • 10.2. Pharmacies
  • 10.3. Veterinary Clinics

11. Veterinary Medicine Market, by Therapeutic Area

  • 11.1. Anti Infectives
    • 11.1.1. Antibiotics
    • 11.1.2. Antifungals
    • 11.1.3. Antivirals
  • 11.2. Anti Inflammatories
  • 11.3. Cardiovascular
  • 11.4. Parasiticides
    • 11.4.1. Ectoparasiticides
    • 11.4.2. Endectocides

12. Veterinary Medicine Market, by Route Of Administration

  • 12.1. Inhalation
  • 12.2. Injectable
  • 12.3. Oral
  • 12.4. Topical

13. Veterinary Medicine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Medicine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Medicine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Zoetis Inc.
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. Boehringer Ingelheim International GmbH
    • 16.3.4. Elanco Animal Health Incorporated
    • 16.3.5. IDEXX Laboratories, Inc.
    • 16.3.6. Ceva Sante Animale S.A.
    • 16.3.7. Vetoquinol S.A.
    • 16.3.8. Virbac S.A.
    • 16.3.9. Dechra Pharmaceuticals plc
    • 16.3.10. Phibro Animal Health Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VETERINARY MEDICINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VETERINARY MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VETERINARY MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY MEDICINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY MEDICINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DOG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DOG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DOG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DOG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DOG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DOG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY EQUINE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY EQUINE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY EQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY EQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY EQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY EQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY HORSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY HORSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY HORSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY HORSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY HORSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY HORSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY OVER THE COUNTER DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY OVER THE COUNTER DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY OVER THE COUNTER DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY OVER THE COUNTER DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY OVER THE COUNTER DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY OVER THE COUNTER DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ONLINE STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ONLINE STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ONLINE STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ONLINE STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ONLINE STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ANTI INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PARASITICIDES, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ENDECTOCIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ENDECTOCIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ENDECTOCIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ENDECTOCIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ENDECTOCIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ENDECTOCIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VETERINARY MEDICINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY EQUINE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY EQUINE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY PARASITICIDES, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS VETERINARY MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY EQUINE, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY EQUINE, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY ANTI INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY ANTI INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY PARASITICIDES, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA VETERINARY MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY COMPANION ANIMAL, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY EQUINE, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY EQUINE, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA VETERINARY MEDICINE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN A